On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review (Q27025624)

language of work or name

1 reference

December 2011

1 reference

1 December 2011

12 references

5 March 2019

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

20 August 2020

6 February 2021

13 references

5 March 2019

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

20 August 2020

6 February 2021

100

1 reference

issue

12

1 reference

page(s)

1523-7

1 reference

Creative Commons Attribution 2.5 Generic

copyright license

12 references

5 March 2019

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

20 August 2020

on focus list of Wikimedia project

6 February 2021

ScienceSource

0 references

cites work

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

VEGF inhibition and renal thrombotic microangiopathy

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Vascular endothelial growth factor: basic science and clinical progress

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Vascular endothelial growth factor and its high-affinity receptor (VEGFR-2) are highly expressed in the human forebrain and cerebellum during development.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

31 May 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

The effect of methotrexate on corneal neovascularization in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2011.02445.X

Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3263420

Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab

28 November 2018

1 reference

12 December 2020

Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney

1 reference

12 December 2020

Alveolar development in the human fetus and infant

1 reference

12 December 2020

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

1 reference

12 December 2020

Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes

1 reference

12 December 2020

Monitoring systemic complications of intraocular medications

1 reference

12 December 2020

Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes

1 reference

12 December 2020

Bevacizumab for retinopathy of prematurity

1 reference

12 December 2020

Pharmacokinetics of intravitreal bevacizumab (Avastin)

1 reference

12 December 2020

Choroidal involution is a key component of oxygen-induced retinopathy

1 reference

12 December 2020

VEGF is required for growth and survival in neonatal mice

1 reference

12 December 2020

Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy

1 reference

12 December 2020

Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways

1 reference

12 December 2020

10.1111/J.1651-2227.2011.02445.X

Identifiers

DOI

1 reference

4480537

4480537

1 reference

1 reference

1 reference